Stocks and Investing
Stocks and Investing
Mon, May 3, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Gary Nachman Maintained (ABBV) at Buy with Increased Target to $129 on, May 3rd, 2021
Gary Nachman of BMO Capital, Maintained "AbbVie Inc." (ABBV) at Buy with Increased Target from $127 to $129 on, May 3rd, 2021.
Gary has made no other calls on ABBV in the last 4 months.
There are 4 other peers that have a rating on ABBV. Out of the 4 peers that are also analyzing ABBV, 0 agree with Gary's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Gary
- Geoffrey Porges of "SVB Leerink" Maintained at Buy with Increased Target to $144 on, Tuesday, March 30th, 2021
- Andrew Baum of "Citigroup" Maintained at Strong Buy with Increased Target to $125 on, Friday, March 12th, 2021
- Randall Stanicky of "RBC Capital" Maintained at Buy with Increased Target to $135 on, Thursday, February 4th, 2021
- David Risinger of "Morgan Stanley" Maintained at Buy with Decreased Target to $116 on, Thursday, January 28th, 2021
Contributing Sources